News & Updates
Filter by Specialty:

Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC
The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.
Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC
15 Jan 2025
Acalabrutinib-venetoclax hits mark for fit TN CLL patients
The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).
Acalabrutinib-venetoclax hits mark for fit TN CLL patients
14 Jan 2025
Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL
The first phase III trial of pirtobrutinib in haematologic malignancies to readout has demonstrated superiority over investigator's choice in delaying progression in pretreated chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL), with results from the BRUIN CLL-321 study first presented at ASH 2024.
Pirtobrutinib scores a phase III win in BTKi-pretreated CLL/SLL
14 Jan 2025
Alectinib trumps crizotinib for ALK+ NSCLC
In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).